Patent intelligence · US
US 7262218
Forms of pravastatin sodium
Forms of pravastatin sodium
Patent details — US 7262218
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 28, 2007
- Expiration
- Aug 23, 2027
- Claims
- 5
- CPC classes
- A61K, A61K31/335, A61P, A61P3/06
Quick answer
US 7262218 (Forms of pravastatin sodium) is held by TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG. Status: granted. Granted Aug 28, 2007. Expires Aug 23, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/335, A61P, A61P3/06, A61P9/10
More from TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 7262218?
US 7262218 (Forms of pravastatin sodium) is held by TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG. Status: granted. Granted Aug 28, 2007. Expires Aug 23, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7262218?
TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 7262218 expire?
Our index shows an expiration date of Aug 23, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.